Antitumor activities of valproic acid on Epstein-Barr virus-associated T and natural killer lymphoma cells

Cancer Science

Volumn 103, Issue 2, 2012, Pages 375-381

  Iwata, Seiko ^a   Saito, Takashi ^a   Ito, Yoshinori ^a   Kamakura, Maki ^a   Gotoh, Kensei ^a   Kawada, Jun ichi ^b   Nishiyama, Yukihiro ^a   Kimura, Hiroshi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b AICHI CHILDREN'S HEALTH AND MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; HISTONE; VALPROIC ACID;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL KILLING; CELL LINE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LYMPHOPROLIFERATIVE DISEASE; NK T CELL LYMPHOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

ADOLESCENT; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CELL CYCLE CHECKPOINTS; CELL LINE; CELL SURVIVAL; CHILD; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LYMPHOMA, NON-HODGKIN; MALE; PYRAZINES; T-LYMPHOCYTES; VALPROIC ACID;

EID: 84856504569     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02127.x     Document Type: Article

References (40)

1. Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000; 343: 481-92.
2. Quintanilla-Martinez L, Kimura H, Jaffe ES. EBV+ T-cell lymphoma of childhood. In: Jaffe ES, Harris NL, Stein H, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. Lyon: IARC Press, 2008; 278-80.
3. Rickinson AB, Kieff E. Epstein-Barr virus. In: Knipe DM, Howley PM, eds. Fields Virology. Philadelphia: Lippincott Williams & Wilkins, 2007; 2655-700.
4. Williams H, Crawford DH. Epstein-Barr virus: the impact of scientific advances on clinical practice. Blood 2006; 107: 862-9.
5. Kieff ED, Rickinson AV. Epstein-Barr virus and its replication. In: Knipe DM, Howley PM, eds. Fields Virology. Philadelphia: Lippincott Williams & Wilkins, 2007; 2603-54.
6. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004; 104: 2635-42.
7. Heslop HE. How I treat EBV lymphoproliferation. Blood 2009; 114: 4002-8.
8. Detich N, Bovenzi V, Szyf M. Valproate induces replication-independent active DNA demethylation. J Biol Chem 2003; 278: 27586-92.
9. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769-84.
10. Kawagoe R, Kawagoe H, Sano K. Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways. Leuk Res 2002; 26: 495-502.
11. Takai N, Desmond JC, Kumagai T et al. Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res 2004; 10: 1141-9.
12. Feng WH, Kenney SC. Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. Cancer Res 2006; 66: 8762-9.
13. Hui KF, Chiang AK. Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death. Int J Cancer 2010; 126: 2479-89.
14. Iwata S, Yano S, Ito Y et al. Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of Epstein-Barr virus infection. Int J Cancer 2011; 129: 2263-73.
15. Zhang Y, Nagata H, Ikeuchi T et al. Common cytological and cytogenetic features of Epstein-Barr virus (EBV)-positive natural killer (NK) cells and cell lines derived from patients with nasal T/NK-cell lymphomas, chronic active EBV infection and hydroa vacciniforme-like eruptions. Br J Haematol 2003; 121: 805-14.
16. Tsuge I, Morishima T, Morita M, Kimura H, Kuzushima K, Matsuoka H. Characterization of Epstein-Barr virus (EBV)-infected natural killer (NK) cell proliferation in patients with severe mosquito allergy; establishment of an IL-2-dependent NK-like cell line. Clin Exp Immunol 1999; 115: 385-92.
17. Kaplan J, Tilton J, Peterson WD Jr. Identification of T cell lymphoma tumor antigens on human T cell lines. Am J Hematol 1976; 1: 219-23.
18. Yagita M, Huang CL, Umehara H et al. A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia 2000; 14: 922-30.
19. Miyoshi I, Kubonishi I, Yoshimoto S et al. Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells. Nature 1981; 294: 770-1.
20. Fujiwara S, Ono Y. Isolation of Epstein-Barr virus-infected clones of the human T-cell line MT-2: use of recombinant viruses with a positive selection marker. J Virol 1995; 69: 3900-3.
21. Robertson MJ, Cochran KJ, Cameron C, Le JM, Tantravahi R, Ritz J. Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp Hematol 1996; 24: 406-15.
22. Isobe Y, Sugimoto K, Matsuura I, Takada K, Oshimi K. Epstein-Barr virus renders the infected natural killer cell line, NKL resistant to doxorubicin-induced apoptosis. Br J Cancer 2008; 99: 1816-22.
23. Iwata S, Wada K, Tobita S et al. Quantitative analysis of Epstein-Barr virus (EBV)-related gene expression in patients with chronic active EBV infection. J Gen Virol 2010; 91: 42-50.
24. Kubota N, Wada K, Ito Y et al. One-step multiplex real-time PCR assay to analyse the latency patterns of Epstein-Barr virus infection. J Virol Methods 2008; 147: 26-36.
25. Patel K, Whelan PJ, Prescott S et al. The use of real-time reverse transcription-PCR for prostate-specific antigen mRNA to discriminate between blood samples from healthy volunteers and from patients with metastatic prostate cancer. Clin Cancer Res 2004; 10: 7511-9.
26. Kimura H, Miyake K, Yamauchi Y et al. Identification of Epstein-Barr virus (EBV)-infected lymphocyte subtypes by flow cytometric in situ hybridization in EBV-associated lymphoproliferative diseases. J Infect Dis 2009; 200: 1078-87.
27. Kimura H, Hoshino Y, Hara S et al. Differences between T cell-type and natural killer cell-type chronic active Epstein-Barr virus infection. J Infect Dis 2005; 191: 531-9.
28. Kimura H, Hoshino Y, Kanegane H et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood 2001; 98: 280-6.
29. Kimura H, Morishima T, Kanegane H et al. Prognostic factors for chronic active Epstein-Barr virus infection. J Infect Dis 2003; 187: 527-33.
30. Cohen JI, Kimura H, Nakamura S, Ko YH, Jaffe ES. Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008. Ann Oncol 2009; 20: 1472-82.
31. Kimura H. Pathogenesis of chronic active Epstein-Barr virus infection: is this an infectious disease, lymphoproliferative disorder, or immunodeficiency? Rev Med Virol 2006; 16: 251-61.
32. Fakih MG, Fetterly G, Egorin MJ et al. A Phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors. Clin Cancer Res 2010; 16: 3786-94.
33. Kirschbaum M, Frankel P, Popplewell L et al. Phase II Study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2011; 29: 1198-203.
34. Niesvizky R, Ely S, Mark T et al. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer 2011; 117: 336-42.
35. Jagannath S, Dimopoulos MA, Lonial S. Combined proteasome and histone deacetylase inhibition: a promising synergy for patients with relapsed/refractory multiple myeloma. Leuk Res 2010; 34: 1111-8.
36. Kawada J, Zou P, Mazitschek R, Bradner JE, Cohen JI. Tubacin kills Epstein-Barr virus (EBV)-Burkitt lymphoma cells by inducing reactive oxygen species and EBV lymphoblastoid cells by inducing apoptosis. J Biol Chem 2009; 284: 17102-9.
37. Kuntz-Simon G, Obert G. Sodium valproate, an anticonvulsant drug, stimulates human cytomegalovirus replication. J Gen Virol 1995; 76: 1409-15.
38. Klass CM, Krug LT, Pozharskaya VP, Offermann MK. The targeting of primary effusion lymphoma cells for apoptosis by inducing lytic replication of human herpesvirus 8 while blocking virus production. Blood 2005; 105: 4028-34.
39. Bazarbachi A, Suarez F, Fields P, Hermine O. How I treat adult T-cell leukemia/lymphoma. Blood 2011; 118: 1736-45.
40. Zain JM, O'Connor O. Targeted treatment and new agents in peripheral T-cell lymphoma. Int J Hematol 2010; 92: 33-44.